SC
ITCI

Samlyn Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Samlyn Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-635,900
Closed -$16.3M – 177
2020
Q2 		$16.3M Buy
+635,900
New +$12.9M 0.3% 75
2017
Q4 		– Sell
-42,200
Closed -$666K – 165
2017
Q3 		$666K Buy
+42,200
New +$619K 0.02% 116

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Samlyn Capital's ITCI Position: Q4 2022 in Review

Samlyn Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2022, closing a stake of 537,888 shares — an estimated $25M sold.

Samlyn Capital first reported a position in ITCI in Q1 2017 and held it in 23 quarters. The position peaked at $58.1M in Q4 2021. 281 funds tracked by Wall St. Rank hold ITCI as of Q4 2022.

  • Samlyn Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2022 after selling out during the quarter.
  • Samlyn Capital sold 537,888 Intra-Cellular Therapies Inc. shares in Q4 2022, an estimated $25M.
  • Samlyn Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2017 and held it in 23 quarters.
  • Samlyn Capital's Intra-Cellular Therapies Inc. position peaked at $58.1M in Q4 2021.
  • 281 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2022.

Based on Samlyn Capital's 13F filing for Q4 2022, filed 14 Feb 2023.